SEC Filing Summary: Celsus Therapeutics Plc (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Celsus Therapeutics Plc on September 1, 2015. The filing addresses a corporate governance event regarding the company's listing status on The NASDAQ Capital Market. Note: The request metadata references "Akari Therapeutics Plc," but the filing text explicitly identifies the registrant as "Celsus Therapeutics Plc."
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial metric disclosed is the market price of the company's American Depositary Shares (ADSs), which closed at or above $1.00 per ADS for at least 10 consecutive business days.
Material Changes
The primary material change is the resolution of a non-compliance issue with NASDAQ Listing Rule 5450(a)(2). Previously, the company's ADS bid price had fallen below the $1.00 minimum requirement for 30 consecutive business days. The company has now regained compliance, and the matter is closed.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operations, or discussion of new risks. The document confirms that the risk of delisting due to the minimum bid price requirement has been mitigated as of the report date.
Key Facts for Investor Verification
- Confirm the current ticker symbol and corporate name, as the filing is for Celsus Therapeutics Plc, not Akari Therapeutics Plc.
- Verify the current trading price of the ADSs to ensure continued compliance with the $1.00 minimum bid price rule.
- Review subsequent filings to confirm no new compliance notices have been issued by NASDAQ.